RenovaCare, Inc. (RCAR)

[bybtrader]

New York & Pittsburgh – January 17, 2017 – RenovaCare, Inc., (OTCQB:RCAR), developer of the patented CellMist™ and SkinGun™ technologies for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today issued its beginning of the year 2017 shareholder update. Below is a statement from Thomas Bold, President and CEO of RenovaCare, Inc.:

Dear Valued Shareholders: Thanks to your support, 2016 was an incredible year for us and our CellMist™ and SkinGun™ technologies for spraying a patient’s own stem cells on to wounds and burns. We closed the year emboldened by the issuance of an important new patent, a string of encouraging pre-clinical and engineering outcomes, and what could be considered by any standard an enviable quantity of media attention. And, we look forward to the year ahead as we move beyond engineering and lab work and on to a focused regulatory pathway to help move our breakthrough products to market.

The future of medicine: rapid, scar-free healing using a patient’s own stem cells.

Our investigational CellMist™ System isolates a patient’s stem cells from a tiny donor skin sample and ultra-gently sprays those regenerative cells on to wounds using our SkinGun™.